500+

Corporate Partner

1300+

Number of Projects

24+

IND/Clinical St

10+

Years Industry Experience

Nanobody

Discovery & Development

Nanobody® is a registered trademark of Ablynx N.V. It is used here for descriptive purposes only.

NBbiolab is a specialized CRO focused on Nanobody (VHH/sdAb) discovery and engineering. Backed by over 10 years of experience and advanced technology platforms, we provide tailored solutions to help our clients accelerate drug discovery and development.

View More

Nanobody

Development Workflow
Antigen Design &
Preparation
Preparation of high-quality antigens with quality validation.
Animal Immunization
Camelid immunization with proprietary adjuvants.
Library Construction
VHH amplification and display library construction.
Library Screening
Phage/Yeast display screening for nanobody binders.
Hit Characterization
Sequencing, expression, purification, and validation.
Humanization
CDR grafting-based humanization with affinity retention.
Final Deliverables
Purified nanobodies, sequences, and validation report.
Nanobody Discovery And Screening Platforms

Home Figure 1. Animal Immunization and Blood Collection

(a) Alpaca immunization procedure. (b) Blood collection from alpaca. (c) 49-day immunization timeline. Black arrows indicate injection days (Days 0, 14, 28, 42), and droplet icons represent blood collection (Days 0, 21, 35, 49). Day 0 serum is used as a negative control, while samples collected after immunization are used to measure immune response by titer testing.

Immunization Service Package

We offer end-to-end support for nanobody generation, from antigen design to immune cell collection. Our standard immunization workflow includes:

● Custom Immunization Strategy – Tailored to your target antigen

● Antigen Design & Production – Protein, peptide, VLP, or nucleic acid formats

● Camelid Immunization – Using naïve alpacas, llamas, or camels

● Serum Titer Monitoring – ELISA and FACS analysis of immune response

● PBMC Isolation & Storage – Peripheral blood mononuclear cells for downstream library construction

View More

To move from immunization to nanobody discovery, we construct high-diversity phage libraries from isolated PBMCs. Each library undergoes stringent validation to ensure quality and performance throughout downstream screening.

Library Construction Highlights

Our platform ensures high-quality phage libraries through rigorous optimization and validation.

1. Primer Optimization – Proprietary primers are designed to comprehensively cover all HcAb germline sequences.

2. Zero-Background Cloning – Background-free cloning technology enables 100% VHH insertion efficiency.

3. High Library Capacity – We guarantee a library size exceeding 1×10⁹ CFUs.

4. Clonal Uniqueness – Sanger sequencing of 48 random clones confirms 100% clonal uniqueness, with no sequence duplication.

5. Sequencing Depth Analysis – ORF correctness exceeds 90% based on sequencing of the sampled clones.

Phage Display Library Construction Workflow

Home

Case Study: Improved Primer Design for Broader VHH Coverage

Standard VHH primers from literature often fail to capture the full diversity of camelid germline sequences. To overcome this limitation, we developed optimized primers that deliver higher PCR amplification efficiency and broader clone diversity.

Home

Figure 1. Agarose gel showing PCR products generated using published VHH primers (top) vs. RayBio’s optimized primers (bottom). Our primers produced more abundant and diverse bands, indicating better amplification and broader germline coverage.

Phage Display Screening Options

Depending on the type and format of your antigen, we offer two proven methods to screen phage libraries:

● Solid-Phase Screening
Antigens are coated directly onto a solid surface (e.g., plate wells). This method is widely used for its simplicity and compatibility with various antigens.

● Liquid-Phase Screening
Biotinylated antigens or antigen-expressing cells are incubated with phage in solution. Phage-antigen complexes are then captured with streptavidin-coated beads. This method better preserves antigen conformation and allows tighter control over concentration—ideal for delicate or complex targets.

Home

Figure 2. Workflow diagram of phage display screening. Shown here are iterative rounds of target binding, washing, elution, and phage amplification to enrich for high-affinity binders.

Service Component

Deliverables

Timeline

Library Construction

Bacterial library

Phage display library

4 weeks

Library Screening

Binder sequences

Project report

4 weeks

View More

Yeast Surface Display (YSD) is a widely used method for screening and selecting high-affinity antibody fragments and other binding proteins. The technique works by inserting the gene of interest into a yeast expression vector, allowing the encoded protein to be displayed on the yeast cell surface. This system enables rapid identification of candidates with desired binding properties, while preserving protein folding and functionality in a eukaryotic environment.

Library Construction Highlights:

Our platform ensures high-quality yeast libraries through rigorous optimization and validation:

● Primer Optimization – Proprietary primers provide broad coverage of HcAb germline sequences

● Zero-Background Cloning – 100% VHH insertion efficiency with background-free cloning

● Large Library Size – Guaranteed capacity exceeding 1×10⁸ CFUs

● Clonal Uniqueness – 100% uniqueness confirmed by Sanger sequencing of 48 random clones

● High ORF Accuracy – >90% correctness rate in open reading frames from validated clones

Yeast Surface Display Library Construction Workflow

Home

Yeast Display Screening Workflow

Following library construction, VHH candidates are screened using dual-selection:

● MACS (magnetic-activated cell sorting) for initial enrichment

● FACS (fluorescence-activated cell sorting) to isolate high-affinity binders

● Binders are validated via sequencing and recombinant expression

Home

Figure 2. Yeast Surface Display Screening Workflow
Overview of the yeast display screening process, from library generation and enrichment to FACS-based selection and hit analysis.

Service Component

Deliverables

Timeline

Yeast Library Construction

Yeast expression library

Bacterial library

4 weeks

Yeast Library Screening

Sequences of binders

Project report

4 weeks

View More

Feature

Phage Display

Yeast Surface Display

Expression System

Prokaryotic

Eukaryotic

Display Level

One copy per phage

104–105 copies per yeast cell

Display Efficiency

≤10%

65%–80%

Antibody Formats

VHH, scFv, peptides, Fab

VHH, scFv, peptides, Fab, IgG

Library Diversity

Limited / Biased

Broad / Unbiased

False Positive Rate

High

Low

Panning Method

Solid or Liquid Phase

MACS and FACS

Compatible Antigen Types

Proteins, Cells

Proteins

Screening Throughput

<1,000 clones (Sanger)

>10,000 clones (NGS)

Representative Targets

BCMA, CLDN18.2, Trop2, GPRC5D, MSLN

BAFFR, PD-L1, IGF-1R, CD16a, HSA, TfR

Ready To Accelerate Your Nanobody Discovery Program?

Submit your project details and receive a customized proposal from our scientists.

Request a Quote
Popular Services

From custom protein or peptide array printing to complete quantitative and/or discovery studies, we can help you advance your multiplex protein analysis projects efficiently and with confidence.

Company Profile

NBbiolab is specialized in developing customized single domain antibodies (sdAb /VHHs) pre-discovery CRo services to support innovative pharmaceutical companies in drug discovery efforts. Established in 2017 in Chengdu, we possess industry-leading Phage Display and Yeast SurfaceDisplay platforms, moreover, our R&D expert team owns more than 10 year's field experience. Wehave been cooperation with more than 300 biotech, bio-pharma companies and universities,which have successfully delivered 1000 sdAb pre-discovery projects and more than 20collaborative projects has approved IND.

View More
Masking Peptide Technologies for Antibody Therapeutics: From Undruggable Targets to Conditionally Activated Medicines
Jul.01,2026

Masking Peptide Technologies for Antibody Therapeutics: From Undruggable Targets to Conditionally Activated Medicines

View More
Antibody Humanization: From CDR Grafting to AI-Driven Multi-Objective Optimization
Jun.30,2026

Antibody Humanization: From CDR Grafting to AI-Driven Multi-Objective Optimization

View More
sdAbs Half-life extension strategy
Jun.22,2026

sdAbs Half-life extension strategy

Oral, injections, inhalation (medication for asthma), topical medication and nasal drops are the five generally drug delivery methods. So How long for a drug to be eliminated from the body after entering it? Here comes the concept of half-life. The half-life of a drug is the time it takes for half of the drug to be eliminated from the body, and it helps determine dosing interval and duration of therapy.
View More